Research in the News
DOR researchers are recognized internationally for their scientific expertise and have contributed more than 3,000 scientific papers about how to use health informatics, manage chronic illness, and motivate self-care and disease prevention.
Kaiser Permanente Teledermatology Finds More Skin Cancers with Fewer Dermatology Visits
With one in five people developing skin cancer, teledermatology is looking for innovative ways to deliver fast and high-quality care to people who need it.
A Better Way to Assess Ovarian Cancer Risk
A new study that estimates the risk for ovarian cancer helps doctors and patients make better choices on whether surgery or ultrasound monitoring is the best option.
Mortality from Colorectal Cancer Declines 52 Percent in Region
KP Northern California members are 52 percent less likely to die from colorectal cancer since TPMG launched a comprehensive, integrated screening program, according to a recent study.
“Catch-up” HPV Vaccination Works for Females up to Age 20 Years at First Dose, Not Older Ages
Kaiser Permanente study confirms recommendations for catch-up HPV vaccination with three doses in females aged 15 to 20, but not when started at or after age 21.
30-Year National Study Shows Women Who Breastfeed for 6 Months or More Reduce their Diabetes Risk by 50%
Erica Gunderson, PhD, MS, MPH, discusses findings in a 30-year study that show the protective effects of breastfeeding for both mothers and their offspring, including lowering a mother’s risk of developing diabetes, breast and ovarian cancer.
New Kaiser Permanente Study Reveals an Increase in Marijuana Use During Pregnancy
Kelly Young-Wolff, PhD, KP Division of Research, and Nancy Goler, MD, discuss their study addressing the increase in maternal prenatal marijuana use, and how the results fill a critical data gap in understanding marijuana use among pregnant women.
Urban American-Indian and Alaskan Natives May Have Lower Survival Following Invasive Prostate and Breast Cancer
Laurel A. Habel, PhD discusses research from TPMG's Division of Research that finds urban American-Indian and Alaskan Native communities are more likely to have lower survival rates following invasive prostate and breast cancer.
Indivior’s Experimental Drug to Fight Opioid Addiction is Approved by the US FDA
Laurel Habel, Ph.D, from TPMG's Division of Research, describes Indivior as a promising alternative to the current addiction medication and believes it will be helpful to patients.
World’s Most Impactful Researchers List Includes Kaiser Permanente Northern California Scientist and Oncologist
TPMG’s Alan Go, MD, from the Division of Research, and oncologist Louis Fehrenbacher, MD, were named as Highly Cited Researchers in clinical medicine for 2017, indicating exceptional scientific impact.